Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915


Delayed Quote. Delayed NASDAQ OMX COPENHAGEN - 10/30 11:59:32 am
410.55 DKK   -3.41%
05:26pNOVO NORDISK : Gets a Buy rating from Bernstein
01:30pNOVO NORDISK A/S : Investor presentation
12:10pNOVO NORDISK : Berenberg gives a Neutral rating
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novo Nordisk A/S : launches new 100% renewable power target for suppliers

share with twitter share with LinkedIn share with facebook
09/21/2020 | 04:35am EDT

Source:Novo Nordisk A/S

September 21, 2020 02:01 ET

Novo Nordisk launches new 100% renewable power target for suppliers

Novo Nordisk will work with all 60,000 of its direct suppliers globally to ensure they are supplying the company based on 100% renewable power by 2030.

The commitment is part of Novo Nordisk's ambition to have zero environmental impact.

Bagsværd, Denmark, 21 September 2020 - Novo Nordisk today announced an ambitious target to ensure all its direct suppliers supply the company based on 100% renewable power by 2030. Novo Nordisk will work with all existing and new suppliers to meet the target. The plan will be presented in connection with Climate Week NYC hosted this week in association with the United Nations and the City of New York.

This commitment is the next step in Novo Nordisk's 'Circular for Zero' environmental strategy, which launched in April 2019 and set an ultimate ambition for the company to have zero environmental impact.

The majority of Novo Nordisk's total carbon emissions originate in its supply chain, making this commitment with suppliers on renewable power integral to achieving Novo Nordisk's environmental strategy. In achieving this target, Novo Nordisk would therefore be eliminating at least 300,000 tons of greenhouse gases from its supply chain. Novo Nordisk has already committed to achieve zero CO2 emissions from the company's own global operations and transport by 2030 and, in 2020, achieved the target of using 100% renewable power across its global production.

"Our ambition of achieving zero environmental impact is a cornerstone of our aspiration to be a truly sustainable business," said CEO Lars Fruergaard Jørgensen. "Achieving it requires that we look beyond our own organisation and collaborate across multiple sectors with suppliers to accelerate the transition to renewable power. We hope that others across the corporate sector will also benefit from these actions. I would like to pay tribute to the commitment of our suppliers, on whom this new ambition depends."

To reach the target, Novo Nordisk will work alongside suppliers, sharing with them what it has learned on embedding renewable power through its operations. Suppliers' ability to meet the 100% renewable power target will be continually evaluated.

SCHOTT, a producer of specialty glass and supplier of pharma packaging to Novo Nordisk, has committed to becoming carbon neutral by 2030. Sourcing renewable power will be one pillar of their company strategy. SCHOTT CEO Dr Frank Heinricht said: "Our transition to carbon neutrality is fuelled by close exchange and collaboration with valued customers. As one example, Novo Nordisk has shared valuable insights from their own experiences of sourcing renewable power. As part of our Zero Carbon strategy, we are taking action to reduce the environmental impact of our operations."

Novo Nordisk hopes that by supporting its suppliers to use renewable power, it will also be contributing to a reduction in emissions more broadly, as other companies may benefit from their suppliers' shift to greater sustainability.

About Novo Nordisk's 'Circular for Zero' environmental strategy

The environmental strategy challenges Novo Nordisk to find new ways to design products that can be recycled or re-used, reshape the business to minimise consumption and waste, and work with suppliers who share the company's goal.

Novo Nordisk is already taking the first steps towards zero environmental impact. But the company is always searching for new ways to do more and believes the answers will come as the business adopts a circular mindset that keeps the products and materials in use. Read more here.

About Novo Nordisk

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 43,500 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.

Further information


Charlotte Zarp-Andersson


30 79 76 03


Ken Inchausti (US)

+1 609 240 9429



Daniel Muusmann Bohsen


3075 2175


Valdemar Borum Svarrer


3079 0301


Ann Søndermølle Rendbæk


3075 2253


Mark Joseph Root


3079 4211


Kristoffer Due Berg (US)

+1 609 235 2989





Novo Nordisk A/S published this content on 21 September 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 September 2020 07:34:05 UTC

share with twitter share with LinkedIn share with facebook
All news about NOVO NORDISK A/S
05:26pNOVO NORDISK : Gets a Buy rating from Bernstein
01:30pNOVO NORDISK A/S : Investor presentation
12:10pNOVO NORDISK : Berenberg gives a Neutral rating
11:43aGLOBAL MARKETS LIVE : Alphabet, Amazon, Starbucks…
09:15aNOVO NORDISK A/S : 3Q Net Profit Rose as Pandemic Disruption EaseD -- Earnings R..
08:49aNOVO NORDISK : Jefferies reaffirms its Sell rating
08:46aNOVO NORDISK : Gets a Buy rating from JP Morgan
08:25aNOVO NORDISK : UBS sticks Neutral
08:11aNOVO NORDISK : Goldman Sachs keeps its Buy rating
05:04aNOVO NORDISK : 3Q Earnings Snapshot
More news
Sales 2020 128 B 19 954 M 19 954 M
Net income 2020 42 215 M 6 604 M 6 604 M
Net cash 2020 10 884 M 1 702 M 1 702 M
P/E ratio 2020 22,4x
Yield 2020 2,17%
Capitalization 954 B 149 B 149 B
EV / Sales 2020 7,39x
EV / Sales 2021 6,91x
Nbr of Employees 43 526
Free-Float 75,1%
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 447,63 DKK
Last Close Price 410,55 DKK
Spread / Highest target 32,7%
Spread / Average Target 9,03%
Spread / Lowest Target -25,7%
EPS Revisions
Lars Fruergaard Jørgensen President & Chief Executive Officer
Helge Lund Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S9.93%154 639
JOHNSON & JOHNSON-5.95%361 159
ROCHE HOLDING AG-6.40%274 461
PFIZER INC.-9.95%196 047
MERCK & CO., INC.-16.56%191 944
NOVARTIS AG-22.62%176 518